Back to search

Cornell University

IN VITRO ENZYMATIC POLYSIALYLATION OF THERAPEUTIC ANTIBODIES USING ENGINEERED GLYCOSYLTRANSFERASES

Abstract

dc:description.abstract

Antibody-based immunotherapy is one of the most significant medical advancement of the 21st century. Monoclonal antibodies (mAb) and their conjugation variants are found to be effective in treating a myriad of conditions including autoimmune and cancer diseases. mAb is a complex biomolecule consisting of multiple polypeptides and post-translational modifications including disulfide bond and N-linked protein glycosylation. Such complexity contributes to a challenge in biomanufacturing, quality assessment, and storage of the mAb, which leads to a high cost of antibody therapy. Hence one of the major objectives of the mAb engineering is to increase its circulating half-life which will help to both reduce therapy cost and improve health care quality. In this work, we proposed using a cell-free glycoengineering strategy to enhance therapeutic antibody half-life. We employed engineered sialyltransferases derived from Campylobacter jejuni and Neisseria meningitidis to extend IgG-Fc N-glycans at the non-reducing end with the polysialic acid polymer. Using our optimized one-pot two-stage biosynthesis protocol, therapeutic antibody Herceptin modified with polysialic acid structure was efficiently produced and structurally validated. The ongoing works including a more extensive structural characterization as well as ex vivo functional assays will be discussed. Taken together, we anticipate cell-free glycoengineering technology producing polysialylated IgG will provide an attractive route for producing therapeutic mAb with enhanced stability and circulating half-life.

Degree

thesis:*
Name thesis:degree_name
M.S., Chemical Engineering
Level thesis:degree_level
Master of Science
Discipline thesis:degree_discipline
Chemical Engineering
Grantor
Cornell University
Year dc:date.issued
2021

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Fu, Jingxin
Chair dc:contributor.chair
  • DeLisa, Matthew
Committee member dc:contributor.committeemember
  • Alabi, Christopher Akinleye

Subjects

dc:subject × 4

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Bibid
15160283
Dc Identifier Other
ProQuest Submission ID: 11236
ProQuest Publication ID: 28649292

Chain of custody

source
Harvested from
Cornell University
Base URL
ecommons.cornell.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Fu, Jingxin. IN VITRO ENZYMATIC POLYSIALYLATION OF THERAPEUTIC ANTIBODIES USING ENGINEERED GLYCOSYLTRANSFERASES. Master of Science thesis, Cornell University, 2021. https://hdl.handle.net/1813/110400